Cargando…

The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck

A significant decrease in %IgG1 accompanied by an increase in %IgG2 in total serum IgG has been previously reported as a highly sensitive marker for detecting early stages of carcinomas of various localizations. Here we investigated the question as to whether this phenomenon is also observed in sera...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderhuber, W, Steinschifter, W, Schauenstein, E, Gotschuli, A, Habermann, W, Fischer, M, Felsner, P, Schauenstein, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362785/
https://www.ncbi.nlm.nih.gov/pubmed/10206292
http://dx.doi.org/10.1038/sj.bjc.6690283
_version_ 1782153540488134656
author Anderhuber, W
Steinschifter, W
Schauenstein, E
Gotschuli, A
Habermann, W
Fischer, M
Felsner, P
Schauenstein, K
author_facet Anderhuber, W
Steinschifter, W
Schauenstein, E
Gotschuli, A
Habermann, W
Fischer, M
Felsner, P
Schauenstein, K
author_sort Anderhuber, W
collection PubMed
description A significant decrease in %IgG1 accompanied by an increase in %IgG2 in total serum IgG has been previously reported as a highly sensitive marker for detecting early stages of carcinomas of various localizations. Here we investigated the question as to whether this phenomenon is also observed in sera of patients with squamous cell carcinoma of the head–neck region (SCC-HN), and to evaluate its diagnostic performance in the post-operative monitoring. Using quantitative affinity chromatography, serum concentrations of IgG1, IgG2 and total IgG were determined in 81 patients with different stages of primary and untreated SCC-HN, in 51 SCC-HN patients in post-therapeutical follow up, and in 33 patients with organ matched benign diseases. The data were compared with a total of 174 healthy controls. It was found that (i) 105 SCC-HN patients exhibited a mean value of 56.0 ± 0.7% IgG1, which likewise differed from healthy controls (63.2 ± 0.5) and benign diseases (61.5 ± 1.0) with P < 0.0005, (ii) sensitivities and specificities for discriminating primary malignancies from healthy controls were 70 and 74% respectively, and from benign diseases 65 and 76%, (iii) highest sensitivities and specificities were observed with post-therapeutic cases suffering from tumour recurrence (88% and 75%) or patients with distant metastases (87% and 86%), (iv) apparently tumour-free post-therapeutic patients showed a mean %IgG1 not different from the normal value. The decrease in %IgG1 accompanied by increased %IgG2 is an efficient, sensitive and early marker of SCC-HN, which appears particularly useful for the post-therapeutic monitoring. © 1999 Cancer Research Campaign
format Text
id pubmed-2362785
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23627852009-09-10 The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck Anderhuber, W Steinschifter, W Schauenstein, E Gotschuli, A Habermann, W Fischer, M Felsner, P Schauenstein, K Br J Cancer Regular Article A significant decrease in %IgG1 accompanied by an increase in %IgG2 in total serum IgG has been previously reported as a highly sensitive marker for detecting early stages of carcinomas of various localizations. Here we investigated the question as to whether this phenomenon is also observed in sera of patients with squamous cell carcinoma of the head–neck region (SCC-HN), and to evaluate its diagnostic performance in the post-operative monitoring. Using quantitative affinity chromatography, serum concentrations of IgG1, IgG2 and total IgG were determined in 81 patients with different stages of primary and untreated SCC-HN, in 51 SCC-HN patients in post-therapeutical follow up, and in 33 patients with organ matched benign diseases. The data were compared with a total of 174 healthy controls. It was found that (i) 105 SCC-HN patients exhibited a mean value of 56.0 ± 0.7% IgG1, which likewise differed from healthy controls (63.2 ± 0.5) and benign diseases (61.5 ± 1.0) with P < 0.0005, (ii) sensitivities and specificities for discriminating primary malignancies from healthy controls were 70 and 74% respectively, and from benign diseases 65 and 76%, (iii) highest sensitivities and specificities were observed with post-therapeutic cases suffering from tumour recurrence (88% and 75%) or patients with distant metastases (87% and 86%), (iv) apparently tumour-free post-therapeutic patients showed a mean %IgG1 not different from the normal value. The decrease in %IgG1 accompanied by increased %IgG2 is an efficient, sensitive and early marker of SCC-HN, which appears particularly useful for the post-therapeutic monitoring. © 1999 Cancer Research Campaign Nature Publishing Group 1999-04 /pmc/articles/PMC2362785/ /pubmed/10206292 http://dx.doi.org/10.1038/sj.bjc.6690283 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Anderhuber, W
Steinschifter, W
Schauenstein, E
Gotschuli, A
Habermann, W
Fischer, M
Felsner, P
Schauenstein, K
The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck
title The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck
title_full The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck
title_fullStr The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck
title_full_unstemmed The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck
title_short The IgG1/G2 subclass shift – a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck
title_sort igg1/g2 subclass shift – a sensitive, tissue non-specific marker for malignancy. diagnostic performance with squamous cell carcinoma of the head and neck
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362785/
https://www.ncbi.nlm.nih.gov/pubmed/10206292
http://dx.doi.org/10.1038/sj.bjc.6690283
work_keys_str_mv AT anderhuberw theigg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT steinschifterw theigg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT schauensteine theigg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT gotschulia theigg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT habermannw theigg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT fischerm theigg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT felsnerp theigg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT schauensteink theigg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT anderhuberw igg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT steinschifterw igg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT schauensteine igg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT gotschulia igg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT habermannw igg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT fischerm igg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT felsnerp igg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck
AT schauensteink igg1g2subclassshiftasensitivetissuenonspecificmarkerformalignancydiagnosticperformancewithsquamouscellcarcinomaoftheheadandneck